Richard Aranda
Chief Tech/Sci/R&D Officer en GOSSAMER BIO, INC. .
Fortuna: 234 583 $ al 31/03/2024
Perfil
Richard Aranda is currently the Chief Medical Officer at Gossamer Bio, Inc. He previously worked as the Vice President-Clinical Development at Receptos LLC from 2015 to 2018, the Vice President-Medical Science & Inflammation at Novo-Nordisk Biochem, Inc. from 2011 to 2015, and as a Principal at Bristol Myers Squibb Co. from 2001 to 2011.
Dr. Aranda obtained his undergraduate degree from the University of California, Santa Cruz and holds doctorate degrees from Stanford University School of Medicine and Stanford School of Medicine.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
GOSSAMER BIO, INC.
0.09% | 18/03/2024 | 198 799 ( 0.09% ) | 234 583 $ | 31/03/2024 |
Cargos activos de Richard Aranda
| Empresas | Cargo | Inicio |
|---|---|---|
| GOSSAMER BIO, INC. | Chief Tech/Sci/R&D Officer | 01/06/2021 |
Antiguos cargos conocidos de Richard Aranda.
| Empresas | Cargo | Fin |
|---|---|---|
| RECEPTOS INC | Corporate Officer/Principal | 01/01/2018 |
| Novo-Nordisk Biochem, Inc. | Corporate Officer/Principal | 01/01/2015 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01/05/2011 |
Formación de Richard Aranda.
| University of California, Santa Cruz | Undergraduate Degree |
| Stanford School of Medicine | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| GOSSAMER BIO, INC. | Health Technology |
| Empresas privadas | 2 |
|---|---|
Receptos LLC
 Receptos LLC Pharmaceuticals: MajorHealth Technology Receptos LLC engages in the provision of developing and commercializing of therapeutic candidates for the treatment of immune and inflammatory diseases. It offers Ozanimod for relapsing multiple sclerosis, Ozanimod for inflammatory bowel disease and RPC4046 for eosinophilic esophagitis. The company was founded by Marcus F. Boehm, Robert J. Peach, William H. Rastetter, Hugh Rosen and Raymond C. Stevens on September 26, 2008 and is headquartered in San Diego, CA. | Health Technology |
| Novo-Nordisk Biochem, Inc. |
- Bolsa de valores
- Insiders
- Richard Aranda
